Shahram Mori, MD
Hematology & Oncology · Orlando, FLNPI 1891001400
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $744,928 of the $951,564 with a category attached, or 78.3%. 32 manufacturers reported payments, led by Incyte Corporation at 47.1% of the total. Among hematology & oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 947 payments — averaging $1004.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$449K
- Amgen$138K
- Syndax Pharmaceuticals, Inc.$92K
- Bristol Myers Squibb$72K
- Sanofi$61K
- Takeda Pharmaceuticals U.S.A., Inc.$47K
- plus $93K from 26 others
Across 131 payments — averaging $4858.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Deciphera Pharmaceuticals Inc.$164K
- Amgen$160K
- Stemline Therapeutics Inc.$144K
- Jazz Pharmaceuticals Inc.$122K
- Pharmacyclics LLC, An Abbvie Company$37K
- Bristol Myers Squibb$10K
- plus $23 from 1 others
What the payments were for
- Consulting fees$61,7646%
- Speaking & faculty fees$744,92878%
- Travel & lodging$125,17713%
- Food & beverage$19,0302%
- Education$6650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 435 | $448,555 |
| Amgen | 119 | $137,546 |
| Syndax Pharmaceuticals, Inc. | 47 | $92,009 |
| Bristol Myers Squibb | 79 | $71,593 |
| Sanofi | 60 | $61,211 |
| Takeda Pharmaceuticals U.S.A., Inc. | 46 | $47,406 |
| Astellas Pharma US Inc | 28 | $25,111 |
| Jazz Pharmaceuticals Inc. | 33 | $20,831 |
| AbbVie | 29 | $18,238 |
| Rigel Pharmaceuticals, Inc. | 9 | $14,349 |
| Sanofi-aventis U.S. LLC | 8 | $6,330 |
| E.r. Squibb & Sons, L.L.C. | 3 | $3,242 |
| Stemline Therapeutics Inc. | 4 | $2,036 |
| Gilead | 13 | $647 |
| Johnson & Johnson | 5 | $497 |
| Daiichi Sankyo Inc. | 5 | $271 |
| Legend Biotech USA Inc. | 4 | $245 |
| GSK | 2 | $241 |
| La Jolla Pharmaceutical Company | 2 | $235 |
| Sobi, Inc | 2 | $197 |
| Pfizer | 2 | $136 |
| Pharmacosmos Therapeutics Inc. | 1 | $124 |
| Beone Medicines USA, Inc. | 1 | $122 |
| Tempus AI, Inc | 1 | $100 |
| Novartis | 2 | $97 |
| Genmab U.S., Inc. | 1 | $77 |
| Melinta Therapeutics, LLC | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Shionogi Inc | 1 | $20 |
| Genetix Biotherapeutics Inc | 1 | $19 |
| Servier Pharmaceuticals LLC | 1 | $18 |
| Genentech USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$951,564 in reported general payments places this provider in the 95th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Acyclovir | 13 | $77 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Orlando
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Daniel LandauOrlando$1.8M
- Sajeve ThomasOrlando$639K
- Nikita ShahOrlando$470K
- Martin DietrichRockledge$6.2M
- Edgardo SantosFort Lauderdale$2M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
- Steven FeinMiami$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.